Elutia(ELUT) - 2025 Q2 - Quarterly Results

Exhibit 99.1 · EluPro Momentum: Second quarter 2025 revenue up 49% sequentially. Total BioEnvelope revenue reached $3.5 million, up 33% year-over-year, with EluPro now contributing about two-thirds of total BioEnvelope sales. · Robust Market Access of EluPro: VAC approvals now more than 160 centers, averaging about 12 new approvals monthly; customer base has grown more than 15x since launch. · Strong Clinical Demand: EluPro customers are delivering meaningfully higher value than our legacy BioEnvelope platf ...